Pieris Pharmaceuticals Inc (PIRS) Expected to Announce Quarterly Sales of $11.39 Million

Brokerages forecast that Pieris Pharmaceuticals Inc (NASDAQ:PIRS) will post sales of $11.39 million for the current fiscal quarter, according to Zacks. Four analysts have issued estimates for Pieris Pharmaceuticals’ earnings, with the lowest sales estimate coming in at $3.70 million and the highest estimate coming in at $30.00 million. Pieris Pharmaceuticals reported sales of $1.34 million during the same quarter last year, which would suggest a positive year-over-year growth rate of 750%. The firm is scheduled to report its next earnings results on Wednesday, May 9th.

According to Zacks, analysts expect that Pieris Pharmaceuticals will report full year sales of $25.77 million for the current financial year, with estimates ranging from $15.80 million to $36.30 million. For the next fiscal year, analysts forecast that the company will report sales of $20.35 million per share, with estimates ranging from $12.00 million to $29.20 million. Zacks’ sales averages are an average based on a survey of analysts that follow Pieris Pharmaceuticals.

How to Become a New Pot Stock Millionaire

Pieris Pharmaceuticals (NASDAQ:PIRS) last issued its quarterly earnings results on Friday, March 9th. The biotechnology company reported $0.17 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.21. Pieris Pharmaceuticals had a negative return on equity of 162.54% and a negative net margin of 69.82%. The company had revenue of $18.15 million during the quarter, compared to the consensus estimate of $7.63 million.

Several research firms have recently weighed in on PIRS. HC Wainwright reiterated a “buy” rating and set a $12.00 target price on shares of Pieris Pharmaceuticals in a research report on Friday, March 9th. Jefferies Group assumed coverage on Pieris Pharmaceuticals in a research note on Monday, March 19th. They issued a “buy” rating and a $12.00 target price on the stock. BidaskClub upgraded Pieris Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Monday, February 5th. ValuEngine upgraded Pieris Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Monday, April 2nd. Finally, Evercore ISI assumed coverage on Pieris Pharmaceuticals in a research note on Monday, March 19th. They issued an “outperform” rating and a $13.00 target price on the stock. One equities research analyst has rated the stock with a sell rating and six have given a buy rating to the company. Pieris Pharmaceuticals has an average rating of “Buy” and a consensus target price of $11.50.

In other Pieris Pharmaceuticals news, major shareholder Orbimed Advisors Llc sold 7,897 shares of Pieris Pharmaceuticals stock in a transaction dated Tuesday, February 13th. The stock was sold at an average price of $8.98, for a total value of $70,915.06. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. 4.05% of the stock is owned by insiders.

Several hedge funds have recently modified their holdings of the company. BlackRock Inc. grew its stake in shares of Pieris Pharmaceuticals by 4.4% during the fourth quarter. BlackRock Inc. now owns 1,596,382 shares of the biotechnology company’s stock worth $12,053,000 after acquiring an additional 67,895 shares during the last quarter. Millennium Management LLC grew its stake in shares of Pieris Pharmaceuticals by 57.9% during the fourth quarter. Millennium Management LLC now owns 699,771 shares of the biotechnology company’s stock worth $5,283,000 after acquiring an additional 256,622 shares during the last quarter. Renaissance Technologies LLC grew its stake in shares of Pieris Pharmaceuticals by 63.7% during the fourth quarter. Renaissance Technologies LLC now owns 650,100 shares of the biotechnology company’s stock worth $4,908,000 after acquiring an additional 253,000 shares during the last quarter. State Street Corp purchased a new stake in shares of Pieris Pharmaceuticals during the second quarter worth about $2,377,000. Finally, Arrowstreet Capital Limited Partnership purchased a new stake in shares of Pieris Pharmaceuticals during the fourth quarter worth about $3,370,000. Institutional investors and hedge funds own 43.99% of the company’s stock.

Shares of NASDAQ:PIRS traded down $0.42 on Wednesday, hitting $6.43. 411,503 shares of the company’s stock were exchanged, compared to its average volume of 626,098. Pieris Pharmaceuticals has a 12 month low of $2.28 and a 12 month high of $9.75. The company has a market cap of $368.91, a price-to-earnings ratio of -16.08 and a beta of 1.71.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by Week Herald and is owned by of Week Herald. If you are viewing this news story on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The legal version of this news story can be viewed at https://weekherald.com/2018/04/21/pieris-pharmaceuticals-inc-pirs-expected-to-announce-quarterly-sales-of-11-39-million.html.

About Pieris Pharmaceuticals

Pieris Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company’s pipeline includes immuno-oncology multi-specifics tailored for the tumor micro-environment, an inhaled Anticalin to treat uncontrolled asthma and a half-life-optimized Anticalin to treat anemia. Its Anticalins proteins are a class of low molecular-weight therapeutic proteins derived from lipocalins, which are naturally occurring low-molecular weight human proteins typically found in blood plasma and other bodily fluids.

Get a free copy of the Zacks research report on Pieris Pharmaceuticals (PIRS)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Pieris Pharmaceuticals (NASDAQ:PIRS)

Receive News & Ratings for Pieris Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pieris Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply